Sisto M, Lisi S, Lofrumento D, DAmore M, Scagliusi P, Mitolo V
HSA and FSA accounts cover the cost, making continuous therapy accessible and affordable for most patients
The chromosome-based rubber tree genome provides new insights into spurge genome evolution and rubber biosynthesis
Comparative overview of the primary pharmacological drivers for the two leading therapeutic classes in MASH: Resmetirom (a THR- agonist) and semaglutide (a GLP1R agonist)
The extended titration schedule helps minimize gastrointestinal adverse effects such as nausea, vomiting, and diarrhea, which are the most common reasons for treatment discontinuation
Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health